Introduction
Until recently the quality of digoxin tablets was assessed by the standard assay arLd determination of disintegration time. This situation improved with the development of methods for assessing the variation in weight of digoxin in individual tablets but since 1971 there have been indications that tablets that meet all of these requirements may vary greatly in the quantity available for gastrointestinal absorption. Investigation of bioavailability of digoxin from branded products marketed in various countries has led to several reports of differences both between brands (Lindenbaum et al., 1971; Manninen et al., 1971; Shaw et al., 1972; Binnion and McDermott, 1972) and between different production batches (Lindenbaum et al., 1971) .
The recent establishment at the Wellcome Research Laboratories of digoxin radioimmunoassay techniques made it possible to assess the bioavailability of digoxin from Lanoxin tablets. It was known that a change in the manufacturing equipment had been made in 1969, and that this change had been reversed in May 1972. Though the standards for digoxin tablets in existence at these times had been fully satisfied it was decided to determine whether bioavailability had been affected by the adjustment. Subsequently, it was decided to test the consistency of bioavailability of recently produced batches of Lanoxin. 6, 8, 10, 12, 14, 24, 27, 32, 48, 51 , and 56 hours after administration. All urine produced by each subject was collected for four days after tablet ingestion. During the first 12 hours urine collection was divided into twohour periods, but was subsequently collected in 12-hour periods. EXPERIMENT B This experiment was designed to compare the bioavailability of batches 1484X, 1745X, 1854X, and 1970X, all of which had been produced since May 1972. These batches were distinct from each other in all phases of production and manufacture, and were selected for the study without reference to the analytical results.
Each volunteer received two tablets (0-5 mg) of Lanoxin on each of four occasions. Each received tablets from each batch, treatment administration being sequenced in accordance with a 4 x 4 Latin square. As in experiment A, tablets were ingested after an overnight fast, and the subsequent procedure was similar. Nevertheless, blood samples were obtained at 15- minute intervals for 2-5 hours, then at 30-minute intervals for 1-5 hours, and at 6, 9, 24, 48, 56, 72, and 80 hours after administration. Further, all urine was collected for 10 days after tablet ingestion. During the first 24 hours urine collection was divided into consecutive 4-, 5-, and 15-hour periods, but was subsequently collected in 24-hour periods. A minimum of 14 days separated each treatment occasion.
DIGOXIN DETERMINATION
Digoxin was determined by a previously described radioimmunoassay method (Lader et al., 1972) in which the tracer used was an iodinated tyrosine derivative of digoxin, and antibody-bound and free digoxin were separated using a double antibody system. All samples were assayed in triplicate. Most plasma samples were assayed neat, but a 1/2 dilution with bovine serum was required for an occasional sample. EXPERIMENT A Peak concentrations were significantly higher (P <0 01) after batch 1484X, as shown in table III. The higher peak values also appeared more rapidly, the mean time to peak being 0-9 hours for 1484X as compared to 2-4 hours for 0953X. The plasma digoxin concentration remained higher after batch 1484X throughout the period studied ( fig. 1) The area under the curve of plasma concentration for 50 hours after each treatment was calculated by using the trapezoidal method. Areas were significantly greater (P <0 05) after batch 1484X (table IV) .
A noticeable difference in urinary digoxin excretion was also apparent. Expressed as a percentage of the administered dose, between subjects or the four treatments. Variability was pronounced in one subject only in whom on one occasion a moderate plasma concentration was sustained for several hours, the maximal value of 1-2 ng/ml occurring 5-5 hours after tablet administration. No reason for this occurrence was deduced. No other instance of delayed, flattened plasma concentration curve was seen, other peak concentrations occurring between 0-5 and 2-5 hours after administration. No consistent difference in the peak time was noted between subjects or treatments. Areas under the plasma concentration curve for 80 hours were fairly consistent for each subject (table VI) , and mean values were highly consistent between the four treatments. Moderate variability in each subject's pattern of digoxin excretion was observed throughout the 10 days' urine collection period, but there was no significant difference between subjects or treatments. Variability between subjects was obvious after batch 1745X only (table VII) , and this was due to low urinary excretion values during the occasion in which the delayed, flattened plasma concentration curve had been noted. Mean values for percentage excretion of the administered dose of each treatment varied from 48-5 to 56-4% after 10 days. (Falch et al., 1973) . In these studies differences in steady state values were surprisingly small, and in conflict with other reports (Stewart and Simpson, 1972; Whiting et al., 1972) . It is apparent that the bioavailability of digoxin from Lanoxin tablets produced in the United Kingdom was reduced by the manufacturing adjustment in 1969, and that this process was reversed in May 1972. At one hospital patients taking 0.5 mg/ day of Lanoxin produced before 1969 showed steady state plasma concentrations of 1.5 ± 0 1 ng/ml (Chamberlain et al., 1970) . Nevertheless, at the same hospital, values of 0 9 ± 0 4 were reported for similar patients taking equal doses of Lanoxin produced after 1969 (Shaw et al., 1972) . It is important to emphasize that Lanoxin tablets produced in the United Kingdom since May 1972 are equivalent in every way with those produced before 1969, as dosage recommendations are based on clinical experience with the latter. It is recommended that a doctor wishing to prescribe Lanoxin to a patient who has never previously received digoxin should follow the well-established regimen, with an expected daily maintenance dosage between 0-25 and 0-5 mg. In countries supplied with Lanoxin tablets produced in the United Kingdom, physicians were warned of the increased bioavailability of recent tablets to prevent a sudden and potentially dangerous increase in absorption in patients already well controlled with Lanoxin. As in the past, it is expected that doctors will adjust dosage according to clinical response. In any patient showing evidence of poor control and no signs of toxicity, progressive increase in daily dosage up to 0 5 mg is recommended. A few patients will require a higher dosage.
Plasma concentration response and cumulative urinary excretion after administration of recently produced Lanoxin tablets resemble those reported after administration of radiolabelled digoxin in alcoholic solution (Doherty et al., 1961; Beermann et al., 1972) . The rapid development of a prominent peak plasma concentration is followed by phases of rapid and slow decline. The rapid phase represents various distribution and elimination processes, and must be highly complex. From six hours after administration the slow decline of plasma digoxin shows first-order characteristics and represents elimination, predominantly by urinary excretion. The rate of elimination in this phase was consistent with previous reports, half life values ranging between 30 and 40 hours. As the assay is most precise in the concentration range of 1 to 4 ng/ml, most confidence can be placed on the urinary measures of digoxin elimination rate. Pharmacokinetic conclusions are also limited by finding that cardioactive metabolites are measured with digoxin in the immunoassay (Stoll, 1972) .
A much lower peak plasma digoxin concentration was shown after Lanoxin produced between 1969 and 1972 than after Lanoxin produced before and after this period. It has been suggested that less risk of transient intoxication would be associated with tablets producing lower peaks (Falch et al., 1973) .
Nevertheless, others have argued that clinical effects are dependent on the digoxin concentration at receptor sites rather than in plasma (Hamer and Chamberlain, 1973) . It is probably only in the steady state that clinical effect relates to plasma concentration. Maximal inotropic and chronotropic effects occur several hours after either oral or intravenous digoxin in man (Gold et al., 1953; Weissler et al., 1966; Shapiro et al., 1970) , presumably after tissue-plasma equilibrium has been established.
It is also reassuring that high peak concentrations occur only after tablets are taken in the fasting state (White et al., 1971) .
The existence of branded and generic tablets of varying bioavailability appears to be a problem with many drugs other than digoxin In the United States a seven-fold differenme in peak plasma digoxin concentrations was found after the same dose of different products (Lindenbaum et al., 1971) . This degree of difference must cause clinically important change if one manufacturer's product is replaced by another. A similar situation is almost certain to exist in other countries. In the United Kingdom Shaw et al. (1972) showed that mean plasma digoxin concentrations of patients in the steady state were similar whether taking Lanoxin produced between 1969 and 1972 or taking digoxin tablets other than Lanoxin. Differences between brands other than Lanoxin would not be apparent in this study. Similarity between two other brands and Lanoxin produced between 1969 and 1972 was also suggested (Hibble et al., 1972) . It may be inferred that many digoxin products on the British market are of low bioavailability, but there is little information on most of the more than 20 individual brands. Evidence of large difference in dissolution rates between many branded tablets has been presented (Beckett and Cowan, 1972) . Until there is reliable information on the relative true potency of digoxin preparations we think it is most unwise to prescribe unspecified digoxin tablets. If a patient adheres to one branded product there will be less risk of sudden change in clinical response.
We have shown that the bioavailability of digoxin from four different batches of recently produced Lanoxin tablets was consistent. Differences in peak plasma digoxin concentrations occurred in some subjects after treatment with different batches, but areas measured under plasma concentration/time curves over many hours showed less variation. Differences in bioavailability between batches of certain branded products may be explained by low content uniformity of the tablets (Vitti et al., 1971; van Oudtshoorn, 1972) , but this could not explain the differences between brands conforming to high standards of content uniformity. Our own experience is that major change in bioavailability can occur without dramatic reduction in content uniformity, and that enforcement of existing regulations in regard to content uniformity would not ensure uniformity of digoxir. bioavailability.
Introduction
Measurement of growth hormone (GH) and cortisol during insulin-induced hypoglycaemia are commonly used to assess pituitary secretion of GH and adrenocorticotrophin (ACTH) (Greenwood et al., 1966) . Stimulation by the recently introduced hypothalamic releasing hormones, thyrotrophin-releasing hormone (TRH) and luteinizing hormone/follicle stimulating hormone-releasing hormone (LH/FSH-RH), now allows "pituitary reserve" for these trophic hormones to be evaluated.
Thyroid-stimulating hormone (TSH) secretion after synthetic TRH has been extensively studied both in normal people and in patients with hypothalamic-pituitary disease (Fleischer et al., 1970; Anderson et al., 1971; Haigler et al., 1971; Ormston et al., 1971; Gual et al., 1972; Hall et al., 1972) . Similarly LH and FSH responses to synthetic LH/FSH-RH have been
